BioCryst Pharmaceuticals (NASDAQ:BCRX) Now Covered by Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research report released on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $20.00 price objective on the biotechnology company’s stock.

BCRX has been the topic of a number of other reports. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Needham & Company LLC restated a “buy” rating and issued a $15.00 price target on shares of BioCryst Pharmaceuticals in a report on Thursday, April 10th. Wedbush started coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price objective on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $11.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, April 11th. Finally, Evercore ISI boosted their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.13.

BioCryst Pharmaceuticals Stock Up 1.4 %

BioCryst Pharmaceuticals stock opened at $8.44 on Tuesday. The company has a market cap of $1.76 billion, a PE ratio of -13.84 and a beta of 1.75. BioCryst Pharmaceuticals has a twelve month low of $4.11 and a twelve month high of $9.50. The company’s 50-day moving average price is $7.68 and its 200-day moving average price is $7.77.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. During the same quarter last year, the business earned $0.28 EPS. The firm’s revenue was up 40.8% on a year-over-year basis. As a group, sell-side analysts expect that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

Several large investors have recently added to or reduced their stakes in BCRX. Vanguard Group Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock worth $164,616,000 after purchasing an additional 1,583,826 shares during the period. Principal Financial Group Inc. lifted its stake in BioCryst Pharmaceuticals by 1,058.1% during the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after acquiring an additional 375,890 shares during the period. Teacher Retirement System of Texas boosted its holdings in shares of BioCryst Pharmaceuticals by 25.1% in the 4th quarter. Teacher Retirement System of Texas now owns 58,291 shares of the biotechnology company’s stock valued at $438,000 after acquiring an additional 11,711 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of BioCryst Pharmaceuticals by 4.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company’s stock valued at $14,890,000 after acquiring an additional 91,998 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter worth $80,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.